subject area of
- Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents Academic Article
- Evolution of anti-HER2 therapies for cancer treatment Academic Article
- Heterogeneity in the definition of dose-limiting toxicity in phase i cancer clinical trials of molecularly targeted agents: A review of the literature Academic Article
- Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma Academic Article
- Population Pharmacokinetics of Sibrotuzumab, A Novel Therapeutic Monoclonal Antibody, in Cancer Patients Academic Article
- Speech-language pathology intervention in a youth justice setting: Benefits perceived by staff extend beyond communication Academic Article